© WHO / Katumba Badru
Dr  Umar, Head of the Ebola Task Force, enters the Ebola isolation ward at Lubaga Hospital in Kampala, Uganda on the 1 November, 2022.
© Credits

Filovirus: Emergency scientific consultation on Bundibugyo medical countermeasures R&D

22 May 2026 13:00 – 16:00 CET

Following the WHO declaration of the ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and Uganda as a Public Health Emergency of International Concern (PHEIC), the Filovirus Collaborative Open Research Consortium (CORC), led by ANRS-MIE, together with Africa CDC and the WHO R&D Blueprint, are convening an urgent scientific consultation to review and align research and development (R&D) priorities for medical countermeasures (MCMs) against Bundibugyo ebolavirus. 

Meeting details

Date: Friday,, 22 May 2026
Time: 13h00–16h00 (CET) Geneva time
Format: Please click on this link to connect Zoom webinar

Questions submitted through the chat function will be reviewed and addressed at appropriate points during the discussion.

The consultation objectives will include:

  • understanding current knowledge on the epidemiology of the disease
  • reviewing what we know about the Bundibugyo ebolavirus natural history
  • reviewing the MCM landscape and available evidence for Bundibugyo ebolavirus
  • discussing clinical trial considerations and research implementation needs
  • identifying immediate and medium-term research priorities
  • identifying priority actions to support a coordinated global R&D response.

Please direct any questions to: corc.filovirus@anrs.fr. We look forward to your participation in this important consultation.

The recording can be accessed here.

Presentations

Experiences and context of the Bundibugyo outbreak: evidence needs and gaps by Jules Villa (Institut Pasteur)

Natural History of Bundibugyo Virus and previous outbreaks by Placide Mbala (INRB) and Barnabas Batamutumbo (UVRI)

Bundibugyo and implications for outbreak response by Barnabas Batamutumbo (UVRI)

EBOla Zaïre Post-Exposure Prophylaxis, preparedness and efficacy evaluation during outbreak in Central and West-Africa

Bundibugyo virus vaccine landscape and data regarding cross protection by Bill Dowling CEPI

Vaccination strategies for filoviruses in the context of the current BDBV outbreak by Bruce Kirenga, Makerere University

Overview of therapeutics R&D approaches for Bundibugyo virus disease by Marco Cavaleri, EMA

Partners Trial by Pauline Byakika (Mbarara University), Placide Mbala (INRB) and Amanda Rojek (Univrsity of Oxford)